Blog
RSS FeedPosted by Michael Wonder on 11 Mar 2018
Is ICER NICEr?
21 February 2018 - Similar to NICE in the UK and the PBAC in Australia, the Institute for Clinical and Economic ...
Posted by Michael Wonder on 22 Feb 2018
A health economics approach to US value frameworks: serving the needs of decision-making
22 February 2018 - Value assessment is an integral component of decision making in health and is the focus of a ...
Posted by Michael Wonder on 20 Feb 2018
Does the USA need a national health technology assessor?
19 February 2018 - In recent years, a small non-profit research organization in Boston, Massachusetts, has quietly acquired a significant ...
Posted by Michael Wonder on 18 Feb 2018
ICER report finds costs of approved CAR-T therapies align with clinical benefit
15 February 2018 - Report will be subject to public deliberation during CTAF meeting on 2 March 2018. ...
Posted by Michael Wonder on 16 Feb 2018
ICER to assess treatments for amyloidosis, prostate cancer in upcoming reports
16 February 2018 - Both reports will be subject of September Midwest CEPAC meeting; open Input now being accepted until 7 ...
Posted by Michael Wonder on 14 Feb 2018
ICER final report: broader benefits of voretigene neparvovec to affected individuals and society provide reasonable long-term value despite high price
14 February 2018 - Appraisal committee vote reveals differences in judgments on value given pricing far above traditional cost-effectiveness levels. ...
Posted by Michael Wonder on 29 Jan 2018
Roche haemophilia drug lowers costs despite high price: ICER
27 January 2018 - A costly new Roche Holding AG drug to treat the bleeding disorder haemophilia A could significantly reduce ...
Posted by Michael Wonder on 26 Jan 2018
Institute for Clinical and Economic Review releases draft evidence report on emicizumab for haemophilia A
26 January 2018 - Public comment period now open until 23 February 23; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 13 Jan 2018
Institute for Clinical and Economic Review Report on voretigene neparvovec suggests substantial price discount needed to meet traditional cost-effectiveness standards
12 January 2018 - Special considerations include patient age, benefit durability, and rarity of condition. ...
Posted by Michael Wonder on 11 Jan 2018
Institute for Clinical and Economic Review posts draft scoping document on elagolix for endometriosis
11 January 2018 - Document open to public comment until 1 February 2018. ...
Posted by Michael Wonder on 06 Jan 2018
Patient-centered decision making: lessons from multi-criteria decision analysis for quantifying patient preferences
26 December 2018 - Patient preferences should be a central consideration in healthcare decision making. ...
Posted by Michael Wonder on 23 Dec 2017
Institute for Clinical and Economic Review's final report on VMAT2 inhibitors for tardive dyskinesia calls for manufacturer and payer action to lower prices and assure adequate access
22 December 2017 - Evidence suggests drugs offer short-term benefits but are vastly overpriced, leading to “low value” designation and triggering ...
Posted by Michael Wonder on 20 Dec 2017
Institute for Clinical and Economic Review releases draft evidence report on CAR-T therapy for B-cell cancers
19 December 2017 - Public comment period open now until 24 January; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 15 Dec 2017
Institute for Clinical and Economic Review to assess elagolix for management of endometriosis
14 December 2017 - Open input now being accepted until 8 January 2018. ...
Posted by Michael Wonder on 05 Dec 2017
Institute for Clinical and Economic Review posts draft scoping documents for two reviews: CGRP inhibitors for migraine and update to prior review of plaque psoriasis treatments
4 December 2017 - Documents open to public comment until 22 December 2017. ...